Care for patients with acute respiratory distress syndrome (ARDS) has changed
considerably over the 50 years since its original description. Indeed, standards of care …

Coronavirus disease 2019 (COVID-19), caused by an infection with the novel coronavirus
SARS-CoV-2, has resulted in a global pandemic and poses an emergency to public health …

In severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, viral load
peaks early and declines quickly after symptom onset. Severe coronavirus disease 2019 …

Background: There is a conflicting body of evidence regarding the benefit of vitamin C,
thiamine, and hydrocortisone in combination as an adjunctive therapy for sepsis with or …

Objetivo Determinar los factores relacionados con la neumonía bacteriana en pacientes con
COVID-19 en una unidad de cuidados intensivos de Barranquilla, Colombia. Diseño …

According to the current evidence, COVID-19 patients are at an increased risk of secondary
pneumonias. The impact of immunosuppressive therapies on superinfections is yet to be …

Phosphodiesterase 4 (PDE4) inhibitors are immunomodulatory drugs approved to treat
diseases associated with chronic inflammatory conditions, such as COPD, psoriasis and …

Background The possible benefits associated with corticosteroid treatment in acute
respiratory distress syndrome (ARDS) patients are not fully known. We conducted an …

The underlying cause of many complications associated with severe COVID-19 is attributed
to the inflammatory cytokine storm that leads to acute respiratory distress syndrome (ARDS) …

В 2020 г. мир столкнулся с беспрецедентным вызовом для людей, связанным со
вторжением нового коронавируса SARS COV-2. Это также вызов и для систем …